Usmani, S. Z., Nahi, H., Legiec, W., Grosicki, S., Vorobyev, V., Spicka, I., . . . Mateos, M. V. (2022). Final analysis of the phase 3 non-inferiority COLUMBA study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma.
Citación estilo ChicagoUsmani, Saad Z., et al. Final Analysis of the Phase 3 Non-inferiority COLUMBA Study of Subcutaneous Versus Intravenous Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma. 2022.
Cita MLAUsmani, Saad Z., et al. Final Analysis of the Phase 3 Non-inferiority COLUMBA Study of Subcutaneous Versus Intravenous Daratumumab in Patients With Relapsed or Refractory Multiple Myeloma. 2022.
Precaución: Estas citas no son 100% exactas.